Skip to main content
Journal cover image

Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data.

Publication ,  Journal Article
Owonikoko, TK; Papadopoulos, KP; Gil-Martin, M; Moreno, V; Salama, AK; Calvo, E; Safran, H; González-Martín, A; Aljumaily, R; Mahadevan, D ...
Published in: Ann Oncol
October 2018

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Ann Oncol

DOI

EISSN

1569-8041

Publication Date

October 2018

Volume

29 Suppl 8

Start / End Page

viii461 / viii462

Location

England

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Owonikoko, T. K., Papadopoulos, K. P., Gil-Martin, M., Moreno, V., Salama, A. K., Calvo, E., … Babiker, H. M. (2018). Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data. Ann Oncol, 29 Suppl 8, viii461–viii462. https://doi.org/10.1093/annonc/mdy289.048
Owonikoko, T. K., K. P. Papadopoulos, M. Gil-Martin, V. Moreno, A. K. Salama, E. Calvo, H. Safran, et al. “Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data.Ann Oncol 29 Suppl 8 (October 2018): viii461–62. https://doi.org/10.1093/annonc/mdy289.048.
Owonikoko TK, Papadopoulos KP, Gil-Martin M, Moreno V, Salama AK, Calvo E, Safran H, González-Martín A, Aljumaily R, Mahadevan D, Niu J, Kal Mohan K, Li J, Stankevich E, Mathias M, Lowy I, Fury MG, Babiker HM. Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data. Ann Oncol. 2018 Oct;29 Suppl 8:viii461–viii462.
Journal cover image

Published In

Ann Oncol

DOI

EISSN

1569-8041

Publication Date

October 2018

Volume

29 Suppl 8

Start / End Page

viii461 / viii462

Location

England

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis